RedHill Biopharma (RDHL) Income from Non-Controlling Interests (2013 - 2014)
RedHill Biopharma's (RDHL) quarterly Income from Non-Controlling Interests came in at $0.07 in Q4 2014, up 40.0% year-on-year from $0.05 in Q4 2013, and up 40.0% on a QoQ basis from $0.05 in Q3 2014.
RedHill Biopharma (RDHL) Income from Non-Controlling Interests (2013 - 2014) Analysis & Trends
RedHill Biopharma (RDHL) has 2 years of Income from Non-Controlling Interests data on file, last reported at $0.07 in Q4 2014.
- On a quarterly basis, Income from Non-Controlling Interests rose 40.0% year-over-year to $0.07 in Q4 2014; TTM through Dec 2014 was $0.21, a N/A change from a year earlier, with the FY2016 full-year figure at $0.24, up 26.32% from the prior year.
- Income from Non-Controlling Interests for Q4 2014 stood at $0.07, up from $0.05 in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for RDHL reached as high as $0.07 in Q4 2014 and fell as low as $0.04 in Q3 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | RedHill Biopharma | 640,064.98 | 640,064.98 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 0.07 |
| Sep 30, 2014 | 0.05 |
| Dec 31, 2013 | 0.05 |
| Sep 30, 2013 | 0.04 |